Serum Neurofilament Light Chain Tracks Acute Injury in Refractory Status Epilepticus

Status epilepticus is a neurological emergency where prolonged seizure activity triggers a cascade of irreversible neuronal death and network alterations [1]. While animal models clearly demonstrate this seizure-induced injury, clinical evidence in humans has historically been limited to small case series, leaving a gap in our ability to quantify real-time brain damage [1, 2]. The challenge is particularly acute in cases of new-onset refractory status epilepticus, where the absence of a clear etiology complicates both treatment and prognosis [3]. Identifying reliable biomarkers of neuro-glial injury is essential for early risk stratification and the potential validation of neuroprotective strategies [1, 4]. Recent advances in fluid biopsy techniques have introduced candidates like neurofilament light chain and S100-beta as potential tools for monitoring acute brain injury in the intensive care unit [5, 6]. A large-scale international study has now evaluated these biomarkers to clarify the trajectory of neuronal damage in patients facing the most severe forms of refractory seizures.